Difference between revisions of "Selpercatinib (Retevmo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 9: | Line 9: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
===[[Non-small cell lung cancer]]=== | ===[[Non-small cell lung cancer]]=== | ||
| − | *5/8/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] | + | *5/8/2020: Granted accelerated approval for adult patients with metastatic [[Biomarkers#RET|RET]] [[Biomarkers#fusion|fusion-positive]] [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Based on LIBRETTO-001)'' |
===[[Thyroid cancer]]=== | ===[[Thyroid cancer]]=== | ||
| − | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary [[thyroid cancer]] (MTC) who require systemic therapy | + | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic [[Biomarkers#RET|RET]]-[[Biomarkers#Alterations|mutant]] medullary [[thyroid cancer]] (MTC) who require systemic therapy. ''(Based on LIBRETTO-001)'' |
| − | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive [[thyroid cancer]] who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). | + | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic [[Biomarkers#RET|RET]] [[Biomarkers#fusion|fusion-positive]] [[thyroid cancer]] who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). ''(Based on LIBRETTO-001)'' |
==Also known as== | ==Also known as== | ||
| Line 20: | Line 20: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
Revision as of 17:49, 26 May 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, LOXO-292 selectively binds to and targets various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity.
Diseases for which it is used
- RET-positive NSCLC
- RET-mutant medullary thyroid cancer
- RET-positive thyroid cancer
History of changes in FDA indication
Non-small cell lung cancer
- 5/8/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Based on LIBRETTO-001)
Thyroid cancer
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Based on LIBRETTO-001)
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Based on LIBRETTO-001)
Also known as
- Code name: LOXO-292
- Brand name: Retevmo